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Abstract
Background: The aim of the present study is to evaluate serum osteoprotegerin (OPG) and soluble receptor
activator of nuclear factor κB ligand (sRANKL) levels in a randomly selected male cohort over 50 years of age and its
association with cystatin C, a cysteine proteinase inhibitor that decreases formation of osteoclasts by interfering at a
late stage of pre-osteoclast differentiation, apart from being a marker of renal function independent of gender,
muscle mass and age; in addition to known predictors such as age, sex hormones, vitamin D, bone mineral density
(BMD) and biochemical markers of bone turnover.
Methods: We determined serum OPG and sRANKL levels and examined its relationship with cystatin C, age, osteocalcin,
C-terminal telopeptides of type-I collagen, procollagen type 1 amino-terminal propeptide, 25-hydroxyvitamin D,
parathyroid hormone, total 17β-estradiol (E2), total testosterone and L1–L4 (LS) and femur neck (FN) BMD data available
from 194 (age, range: 51–81 years) randomly selected ambulatory men belonging to the HunMen cohort.
Results: OPG correlated significantly with age (Spearman’s rho (r) = 0.359, p < 0.001), cystatin C (r = 0.298, p < 0.001),
E2 (r = 0.160, p = 0.028) and free testosterone index (FTI) (r = −0.230, p = 0.001). Compared to the middle-aged
(age: ≤ 59 years, n = 98), older men (age > 59 years, n = 96) had significantly higher serum OPG (4.6 pmol/L vs.
5.4 pmol/L; p < 0.001), and lower sRANKL (0.226 pmol/L vs. 0.167 pmol/L; p = 0.048) levels. The older men
showed a significant correlation between serum OPG levels and cystatin C (Spearman’s rho = 0.322, p = 0.002),
and E2 (Spearman’s rho = 0.211, p = 0.043). Including cystatin C and E2 in a regression model showed that
cystatin C (standard regression coefficient (β) = 0.345; p = 0.002) was the only significant predictor of serum
OPG levels in the older men.
Conclusions: The results of this study demonstrated that in addition to age (which was the stronger predictor),
other modifiable factors such as cystatin C, FTI and E2 were also significant predictors of OPG, and that the
association between cystatin C and OPG was more evident with increased age (older age group). As such,
cystatin C is a significant predictor of OPG independently of age, FTI and E2.
Background
Osteoprotegerin (OPG) and receptor activator of nuclear
factor-κB ligand (RANKL), two members of the tumor
necrosis factor receptor super family, are essential in the
regulation of bone resorption [1, 2]. OPG is a soluble
decoy receptor, secreted by osteoblasts and other cell types,
and competitively binds RANKL. RANKL is expressed
primarily by osteoblasts and its receptor RANK is ex-
pressed in preosteoclasts and other cells of this lineage.
When RANKL binds to RANK, osteoclastogenesis and
bone resorption are induced. Thus, bone resorption may
be prevented by OPG binding to RANKL [3]. In addition
to being a key regulator of osteoclastogenesis, the OPG/
RANKL/RANK system is reported as being a significant
mediator between factors such as estradiol, testosterone,
parathyroid hormone, vitamin D, and bone turnover [3–6].
Data on OPG and RANKL levels in healthy men is
accumulating [7–19]. Nonetheless, based on published
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data, it may well be generalized that the association be-
tween OPG/RANKL and its predictors is lacking consen-
sus. Furthermore, the association of cystatin C with OPG
and RANKL has only been limitedly investigated in the
healthy, where no significant correlation was found [14].
Nonetheless, in-vitro studies have implied that cystatin C
is a cysteine proteinase inhibitor that decreases osteoclas-
togenesis by interfering at a late stage of pre-osteoclast
differentiation [20, 21]. Additionally, cystatin C possesses
the advantage of being independent of gender, muscle
mass and age; and consequently may qualify better than
creatinine as a surrogate marker of renal function in in-
vestigating the role of decreased protein clearance as a
potential cause of age-related OPG elevation [22]. The
aim of the present study is to evaluate serum OPG and
RANKL levels in a randomly selected male cohort over
50 years of age and its association with cystatin C, age, sex
hormones, vitamin D, bone mineral density (BMD) and
biochemical markers of bone turnover.
Methods
Subjects
The fasting serum samples (n = 194) for OPG and soluble
RANKL (sRANKL) determinations belonged to partici-
pants in the HunMen cross-sectional, observational study
[23]. Briefly the HunMen study was a local initiative to
evaluate the bone health of randomly selected healthy
men who confirmed to the inclusion and/or did not con-
firm to the exclusion criteria. Recruitment was between
September 2009 and September 2010. Inclusion criteria
were: over 50 years of age, male, ambulatory, commu-
nity dwelling and generally regarded as healthy. Exclu-
sion criteria were: known prevalent metabolic bone
disease, liver or renal disease and use of medication
influencing bone metabolism (excluding calcium and
vitamin D supplementation). The study was approved by
the ethics review board of the University of Debrecen,
Hungary in compliance with the Declaration of Helsinki,
and all subjects gave written informed consent.
Study procedures
Dual energy X-ray absorptiometry examination was per-
formed using the LUNAR Prodigy (GE-Lunar Corp.,
Madison, Wisc., USA) densitometer. BMD was measured
at L1–L4 lumbar spine (LS) and femur neck (FN). The
coefficient of variation (CV) of the technique at our ins-
titute was 0.8 % using the anatomical spine phantom
measured daily.
Serum total OPG and sRANKL were measured using
enzyme immunoassays (Biomedica Gruppe, Biomedica
Medizinprodukte GmbH & Co KG, Wein, Austria). The
OPG assay, that detects monomeric dimeric and ligand
bound OPG, uses a monoclonal mouse anti-OPG antibody
as capture antibody and a biotin-labeled goat polyclonal
antibody for detection. The sRANKL assay, that detects
soluble, uncomplexed human RANKL, uses human recom-
binant OPG for capture and a biotin-labeled goat poly-
clonal antibody for detection. Plasma 25-hydroxyvitamin D
(25-OH-D) was analyzed by high pressure liquid chroma-
tography (HPLC) using a Jasco HPLC system (Jasco, Tokyo,
Japan) and Bio-Rad reagent kit (Bio-Rad Laboratories,
Hercules, CA, USA). Serum estradiol (E2), testosterone (T),
sex hormone binding globulin (SHBG), parathyroid hor-
mone (PTH), osteocalcin (OC), C-terminal telopeptides of
type-I collagen (CTx), procollagen type 1 amino-terminal
propeptide (PINP) were measured using electrochemi-
luminiscence immunoassay (Roche Diagnostics GmbH,
Mannheim, Germany). The inter-assay CV was <8 % for
OPG (lower detection limit: 0.14 pmol/L, upper detection
limit: 30 pmol/L), <6 % for sRANKL (lower detection
limit: 0.02 pmol/L, upper detection limit: 2 pmol/L),
<3.5 % for 25-OH-D (25-OH-D2 - lower detection limit:
13.1 nmol/L, upper detection limit: 606 nmol/L; 25-OH-
D3 - lower detection limit: 16.5 nmol/L, upper detection
limit: 624 nmol/L), <7 % for E2 (lower detection limit:
0.018 nmol/L, upper detection limit: 15.78 nmol/L), <9 %
for T (lower detection limit: 0.087 nmol/L, upper detec-
tion limit: 52 nmol/L), <6 % for SHBG (lower detection
limit: 0.350 nmol/L, upper detection limit: 200 nmol/L),
<7 % for PTH (lower detection limit: 0.127 pmol/L, upper
detection limit: 530 pmol/L), <4 % for OC (lower detec-
tion limit: 0.5 μg/L, upper detection limit: 300 μg/L), <7 %
for CTx (lower detection limit: 0.010 μg/L, upper detec-
tion limit: 6 μg/L) and <6 % for PINP (lower detection
limit: 5 μg/L, upper detection limit: 1200 μg/L).
Plasma cystatin C was measured using particle-enhanced
nephelometric immunoassay (Siemens Healthcare Diagnos-
tics Products GmbH, Marburg, Germany), its inter-assay
CV was <4 % (lower detection limit: 0.05 mg/L, upper
detection limit: 7.58 mg/L). Creatinine was measured using
the Creatinine Jaffé 2nd generation (compensated) test
on the cobas c 111 system (Roche Diagnostics GmbH,
Mannheim, Germany). The free estradiol index (FEI)
and free testosterone index (FTI) was calculated as the
total 17β-estradiol to SHBG ratio and total testoster-
one to SHBG ratio, respectively. The 4-variable modifica-
tion of diet in renal disease (MDRD) study equation was
used for calculating eGFR [24]. Additionally, eGFR was
also calculated using the chronic kidney disease-
epidemiology collaboration (CKD-EPI) cystatin C and
CKD-EPI creatinine-cystatin C equations [25, 26].
Statistical analysis
Kolmogorov-Smirnov test was used for the evaluation of
the normality of the data. Most parameters were non-
normally distributed; therefore analyses were performed
by Mann–Whitney U test. The Spearman’s rho was cal-
culated for correlation analysis. Associations were tested
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using linear regression analysis after log transformation
of not normal variables. Additionally, to reduce the con-
founding effect of age, the median age was used to form
two subgroups. A value of p < 0.05 was considered statis-
tically significant. All analyses were performed with the
SPSS Statistics software, version 19.0 (IBM Corps.,
Armonk, NY, USA).
Results
In the HunMen study, a total of 229 randomly selected
volunteers agreed to participate. volunteers not confirm-
ing to the inclusion and/or confirming to the exclusion
criteria (n = 23) were excluded from the study’s final sta-
tistical analysis. The HunMen study was not designed
primarily for the aim of this study, and only 194 samples
were available for serum OPG and sRANKL determin-
ation from a total of 206 participants. The general charac-
teristics of the subjects (n = 194) are presented in Table 1.
OPG significantly correlated with age, cystatin C, E2
and FTI (Table 2).
Furthermore, Cystatin C correlated with age (Spearman’s
rho = 0.377, p < 0.001), creatinine (Spearman’s rho = 0.487,
p < 0.001), MDRD eGFR (Spearman’s rho = −0.524,
p < 0.001), E2 (Spearman’s rho = 0.222, p = 0.003),
P1NP (Spearman’s rho = 0.151, p = 0.040) and OPG
(Spearman’s rho = 0.298, p < 0.001). Although OPG did
not correlate with serum creatinine or MDRD eGFR, it
did show a significant correlation with cystatin C-eGFR,
and cystatin C and creatinine-eGFR.
Multivariate linear regression analysis was carried out to
determine the statistically significant predictors of serum
OPG levels. Including age, cystatin C, FTI and E2 in a
regression model showed that age, cystatin C, FTI and E2
were significant predictors of serum osteoprotegerin levels
(Table 3).
In order to reduce the confounding effect of age, using
the median age of 59 years, the study population was
divided into a middle-aged (those ≤ 59 years of age, n = 98)
and an older (those > 59 years of age, n = 96) sub-group.
Compared to the middle-aged (age: ≤ 59 years, n = 98),
older men had significantly higher serum OPG and sig-
nificantly lower RANKL levels and RANKL/OPG ratios
(Table 1). The middle-aged individuals showed no signifi-
cant correlation between serum OPG and sRANKL levels
and the other studied parameters (Table 2). The older men
showed a significant correlation between serum OPG levels
and cystatin C. Including cystatin C and E2 in a regression
model showed that cystatin C (standard regression coeffi-
cient (β) = 0.345; p = 0.002) was the only significant pre-
dictor of serum OPG levels in the older men.
There was no statistically significant difference in the
group with non-detectable (<0.02 pmol/L, n =74) sRANKL
Table 1 Subject characteristics
All men (n = 194) Middle-aged men
(≤59 years of age, n = 98)
Older men
(>59 years of age, n = 96)
Age, years (mean, range) 60.4 (51–81) 55.6 (51–59)* 65.4 (60–81)*
Body mass index, kg/m2 (mean, range) 29.2 (17.3–41.7) 28.9 (18–38.5) 29.5 (17.3–41.7)
Osteoprotegerin, pmol/L (mean, range) 5.0 (2.2–10.1) 4.6 (2.2–7.7)** 5.4 (3.0–10.1)**
sRANKL, pmol/L (mean, range)













Total 17-β-Estradiol, nmol/L (mean, range) 0.09 (0.02–0.19) 0.09 (0.03–0.19) 0.08 (0.02–0.15)
Total testosterone, nmol/L (mean, range) 12.8 (0.3–41.7) 13.1 (2.7–41.7) 12.4 (0.3–32.1)
Sex hormone binding globulin, nmol/L (mean, range) 40.8 (12.3–196.2) 40.7 (12.7–196.2) 40.9 (12.3–115.5)
Free Estradiol Index (mean, range) 0.0026 (0–0.009) 0.0026 (0.001–0.007) 0.0025 (0–0.009)
Free testosterone Index (mean, range) 0.3398 (0.005–0.743) 0.354 (0.081–0.704)***** 0.325 (0.005–0.743)*****
PTH, pmol/L (mean, range) 4.2 (1–10.2) 4.2 (1–10.2) 4.3 (1.6–8.3)
25-hydroxy-vitamin D, nmol/L (mean, range) 73.1 (11–185) 72.1 (11–137) 74.0 (14–185)
Osteocalcin, μg/L (mean, range) 14.6 (5–35) 15.2 (5–33) 14.0 (6–35)
C-terminal telopeptides of type-I collagen, μg/L (mean, range) 0.22 (0.01–0.77) 0.24 (0.01–0.77) 0.20 (0.04–0.70)
PINP, μg/L (mean, range) 38.3 (10.5–98.6) 39.2 (10.5–98.6) 37.3 (13.1–81.3)
Cystatin C, mg/L (mean, range) 0.697 (0.381–1.150) 0.657 (0.381–1.060)****** 0.736 (0.485–1.150)******
L1-L4 bone mineral density, gm/cm2 (mean ± SD) 1.172 ± 0.185 1.148 ± 0.167 1.197 ± 0.199
Femur neck bone mineral density, gm/cm2 (mean ± SD) 0.970 ± 0.137 0.980 ± 0.131 0.960 ± 0.142
sRANKL Soluble receptor activator of nuclear factor – κB ligand, PINP Total procollagen type 1 amino-terminal propeptide
*,**,******p < 0.001, ***p = 0.048, ****p = 0.007 and *****p = 0.049 between middle-aged and older men
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concentrations as compared to those with detectable (≥0.02
pmol/L, n =120) sRANKL concentrations in the studied
parameters, except for LS (1.190 (0.810-1.892) vs. 1.143
(0.749-1.855) gm/cm2; p = 0. 043) and FN (0.984 (0.646-
1.281) vs. 0.949 (0.602-1.331) gm/cm2; p = 0.049) BMD. As
such, LS and FN BMD is significantly lower in those with
undetectable sRANKL levels.
There was no difference in OPG, sRANKL and
sRANKL/OPG ratio upon comparing the vitamin D
sufficient (25-OH-D ≥ 75 nmol/L) with the vitamin D
insufficient (25-OH-D < 75 nmol/L) individuals.
Discussion
Our results demonstrate that serum OPG levels increase
and sRANKL/OPG ratio decreases with age in healthy
men over 50 years of age. With regards to the relation-
ship of OPG with age, our findings are in tune with
those reported by others (7–10,12,14-19). As enumer-
ated in Table 4, among the various predictors studied,
perhaps the positive correlation of OPG with age is the
only finding showing consensus in the different studies
to date. The only exception with this regards is the non-
significant finding by Oh et al., where the lack of correl-
ation may be due to the limited number of cases studied
(n = 80) and a relatively lower age maximum of the study
population (i.e., 70 years).
With regards to the correlation of OPG with BMD and
biochemical markers of bone turnover, as per the results of
the studies published to date, statistically significant posi-
tive, negative and non-significant findings have been pre-
sented (see Table 4). Our finding of non-significance only
contributes to the need for further studies. Knowing that
OPG messenger ribonucleic acid (mRNA) is expressed in a
variety of tissues, including lung, kidney and heart, multiple




(≤59 years of age, n = 98)
Older men
(>59 years of age, n = 96)
r p r p r p
Age 0.359 <0.001 0.165 0.105 0.050 0.631
Body mass index 0.031 0.672 0.057 0.580 −0.036 0.725
sRANKL −0.034 0.713 0.019 0.885 −0.038 0.774
sRANKL/Osteoprotegerin ratio −0.234 0.010 −0.204 0.116 −0.199 0.131
Total 17-β-Estradiol 0.160 0.028 0.164 0.110 0.211 0.043
Total testosterone −0.025 0.729 0.106 0.302 −0.064 0.540
Sex hormone binding globulin 0.070 0.342 0.199 0.052 0.060 0.568
Free Estradiol Index −0.072 0.323 −0.084 0.414 0.048 0.648
Free testosterone Index −0.230 0.001 −0.142 0.167 −0.169 0.106
Parathyroid hormone −0.076 0.300 −0.172 0.093 −0.009 0.930
25-hydroxy-vitamin D −0.123 0.091 −0.115 0.085 −0.030 0.774
Osteocalcin −0.102 0.161 −0.037 0.717 −0.040 0.706
C-terminal telopeptides of type-I collagen −0.100 0.171 −0.095 0.358 −0.053 0.611
PINP −0.043 0.553 −0.006 0.951 −0.044 0.667
L1-L4 bone mineral density 0.026 0.716 −0.041 0.689 0.010 0.923
Femur neck bone mineral density −0.074 0.307 −0.071 0.485 −0.001 0.995
Cystatin C 0.298 <0.001 0.022 0.832 0.322 0.002
Creatinine 0.038 0.618 −0.085 0.415 0.132 0.239
MDRD-eGFR −0.071 0.351 0.083 0.428 −0.142 0.207
Cystatin C-eGFR −0.343 <0.001 −0.031 0.766 −0.335 0.001
Cystatin C and creatinine-eGFR −0.231 0.003 0.023 0.834 −0.262 0.020
sRANKL Soluble receptor activator of nuclear factor – κB ligand, PINP Total procollagen type 1 amino-terminal propeptide





Total 17-β-Estradiol 0.166 0.021
Free testosterone Index −0.178 0.012
Cystatin C 0.182 0.015
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tissues contribute together to circulating OPG, as such
measurement of OPG levels in the bone microenvironment
is most desirable [27].
Our finding of statistically significant positive correlation
between E2 with OPG, along with those reported by Schulz
et al. and Indridason et al., supports the finding that E2
increases OPG mRNA steady state levels and protein
production in a human estrogen-responsive osteoblastic
cell line [4]. Furthermore, Khosla et al. have demonstrated
that estrogen treatment increases OPG levels in adult men
[9]. Our finding of negative correlation between testoster-
one and OPG supports two and disagrees with another 2
previous studies [5, 7, 8, 14]. Nonetheless, the negative
correlation supports the finding by Khosla et al. where it
Table 4 Literature data on correlation coefficients (with p values) between serum osteoprotegerin levels in men and the studied
parameters
Authors Age BMD T E2 FEI FTI PTH 25-OH-D Creatinine Bone markers
Szulc et al. [7] r = 0.41 n.s. n.s. n.s. ar = 0.18 ar = 0.31 r = −0.23 n.s. n.s. br = −0.20
p < 0.01
p = 0.0001 p < 0.02 p = 0.0001 p < 0.01
Khosla et al. [8] r = 0.39 cr = −0.17 r = −0.16 n.s. dn.s. er = −0.27 - - - fr = 0.16
p < 0.05
p < 0.001 p < 0.05 p < 0.05 p < 0.001 gr = 0.26
p < 0.001
Khosla et al. [9] - - - - - - - - - hn.s.




Trofimov et al. [12] r = 0.42 n.s. n.s. n.s. - - - - - -
p < 0.001
Oh et al. [13] n.s. jr = −0.259 n.s. r = −0.319 - - - - - kr = −0.25
p = 0.024
p = 0.020 p =0.004
Indridason et al. [14] ip < 0.05 lr = −0.13
p≤ 0.05
- - nr = 0.15 or = 0.09
p≤ 0.001





Mazziotti et al. [15] r = 0.37
p = 0.002
- - - - - - - rr = 0.46 sr = 0.47
p≤ 0.05
p≤ 0.05
Stern et al. [16] r = 0.552 tp < 0.05 - - - - - - - -
p < 0.001
Samelson et al. [17] up < 0.05 vn.s. - - - - - - wp < 0.05 -
Jorgensen et al. [18] r = 0.52 xp = 0.001 - - - - - - - -
p < 0.001
Szulc et al. [19] - yr = −0.28 - - - - - - - zr = −0.10
p < 0.05




This study r = 0.359
p < 0.001
n.s. n.s. r = 0.16
p = 0.028
n.s. r = −0.23
p = 0.001
n.s. n.s. acn.s. n.s.
BMD bone mineral density, T testosterone, E2 17β-estradiol, FEI free estradiol index, FTI free testosterone index, PTH parathyroid hormone, 25-OH-D 25-hydroxyvitamin D,
n.s. statistically non significant
aAfter adjustment for age and body weight in > 40 years of age, burinary total deoxypyridinoline (DPD) after adjustment for age in > 40 years of age, cmid-radius
in ≥ 50 years of age, dr = −0.18 (p < 0.05) for bioavailable E2 in ≥ 50 years of age, er = −0.27 (p < 0.001) for bioavailable T in ≥ 50 years of age, furinary N-telopeptide
of type I collagen (NTx), gurinary free DPD, hurinary NTx and DPD, istatistically significant positive correlation, but r value is not mentioned, jlumbal spine (LS),
kosteocalcin (OC), ltotal body, mhip, n,ocalulated free sex hormone levels, pn.s. for cystatin C, qserum C-terminal cross-linked telopeptides of type I collagen (CTx),
rin a group including men and women (n = 52) aged between 65 and 84 years, sserum CTx in a group including men and women (n = 52) aged between 65 and
84 years, tLS (statistically significant positive correlation, but r value is not mentioned), uage increased (Trend, p < 0.05) with increasing quartile of osteoprotegerin
(OPG), vage-adjusted femur neck BMD showed no difference between OPG quartiles, wglomerular filtration rate (GFR) decreased (Trend, p < 0.05) with increasing
quartile of OPG, xage-adjusted distal forearm BMD decreased (Trend, p = 0.001) with increasing OPG tertile, ytotal (distal radius and tibia) vBMD above the median
OPG level, zOC and N-terminal extension type 1 collagen propeptide (P1NP) below the median OPG level, aaurinary DPD and abserum CTx above the median OPG
level, acn.s. with creatinine and GFR but r = 0.298 (p < 0.001) with cystatin C
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was demonstrated in vivo that testosterone therapy resulted
in lower OPG levels [9].
Our finding of non-correlation of age with sRANKL
is in accordance with that reported earlier [11–13, 15,
16, 18]. Upon bivariate analysis we found no correlation
between sRANKL and BMD, this finding is in agree-
ment with that of Trofimov et al. and Oh et al., but in
disagreement with the findings of Stern et al., who
reported an inverse association between RANKL and
BMD [12, 13, 16]. Nonetheless, we observed statistically
higher FN and LS BMD in those with detectable
(higher) sRANKL levels, this finding, at least in part,
may explain the low risk of non-traumatic fracture in
participants in the highest tertile of RANKL in the study
by Schett et al. [11]. It needs to be pointed out that
Schett et al. found no relationship between sRANKL
and bone ultrasound data and they did not carry out
BMD measurements in their study population [11].
Adding to the controversy is the finding by Jorgensen
et al., where they found no difference in BMD between
those with detectable versus non-detectable sRANKL
levels [18]. Although the present generation of sRANKL
immunoassays has a better lower detection limit than
its predecessors, methodology with improved detection
limits are most desired. Probably introduction of more
sensitive immunoassays may help quantify undetectable
sRANKL levels and perhaps may help explore
relationships between those with low sRANKL and its
known predictors.
As far, the one study that studied the relationship of
sRANKL/OPG ratio with age found no significance with
this regards, in contrast to this our study reports a nega-
tive correlation between the ratio and age. This finding
certainly needs validation by others.
Although it is suggested that PTH has a suppressive ef-
fect on OPG production, the present study did not find any
correlation between PTH and OPG [28, 29]. Our results
are in agreement with those of Indridason et al. and in con-
trast to those of Szulc et al. and Kudlacek et al. [7, 10, 14].
In contrast to the finding that 1,25 dihydroxyvitamin D
stimulates OPG production, in vivo studies in healthy men,
including the present study, have not found any correlation
between 25-OH-D, an index of body vitamin D status, and
OPG [7, 10, 14, 30, 31].
In summary, the non-agreement between findings
from different studies may be explained, at least
partially, by the different assay methodology, in some
cases the use of frozen samples more than a decade old,
the different recruitment criteria used in the selection
of the cohort, the size of the study sample and perhaps
the age composition of the cohorts studied.
The role of decreased protein clearance as a potential
cause of age-related OPG elevation has been considered
in a few previous studies [15, 17, 19]. Mazzioti et al.
found a significant positive correlation between creatin-
ine and OPG, and Samelson et al. found that with in-
creasing quartiles of OPG the GFR decreased
significantly [15, 17]. This finding is in contrast to the
results of Szulc et al., where no correlation was found
between OPG and creatinine [19]. Our findings show
that there is no correlation between OPG and eGFR,
when the MDRD equation is used, but there is a signifi-
cant negative correlation using the CKD-EPI cystatin C
and the CKD creatinine-cystatin C equations. This find-
ing may illustrate the importance of the type of equation
used to calculate eGFR. Nonetheless, the combined
creatinine-cystatin C equation is considered to perform
better than equations based on either of these markers
alone [25, 26]. We found a strong positive correlation
between OPG and cystatin C. Our positive finding is in
contrast to that of Indridason et al., where no such
correlation was found [14]. Although the assay method-
ology used by Indridason et al. is not the one used by
us, this difference alone does not explain the difference
in the observations of the two studies. Nonetheless,
serum OPG has been shown to correlate positively in
male patients with chronic renal failure [32].
Although the study participants were members of a
well-defined healthy cohort randomly selected from the
population, there are limitations to our study. The
HunMen study was not designed primarily for the aim
of this manuscript, and only 194 samples were available
for serum OPG and sRANKL determination from a total
of 206 participants [20]. In addition, we were not in a
position to study the effects of bioavailable (free) sex
hormones on OPG, instead we used calculated free sex
hormone indices to carry out the different statistical
analysis. Although the mechanism of the effect, as a
renal marker or inhibitor of osteoclastogenesis, of
cystatin C on OPG levels cannot be elucidated by the
findings of the present study, we have found that it is a
significant predictor of serum OPG levels. These
findings need verification and further studies are
necessary.
The present study confirms to the STROBE State-
ment, a checklist of items that should be included in
reports of observational studies has been provided as
Additional file 1 [33].
Conclusion
The present study demonstrated that in addition to age,
the stronger predictor, other adjustable factors such as
cystatin C, FTI and E2 were also significant predictors
of OPG. Furthermore, the association between cystatin
C and OPG was more evident with increased age. In
conclusion, cystatin C is a significant predictor of OPG
independently of age, FTI and E2.
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Additional file 1: STROBE Statement—checklist of items that
should be included in reports of observational studies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Study Design: AB, PAS, HPB. Study conduct: EKJ, ZsP, EK, RF, AB, PAS, HPB.
Data collection: EKJ, ZsP, AB, HPB. Data interpretation: EKJ, ZsP, ZoP, AB, PAS,
HPB. Drafting manuscript: EKJ, ZsP, HPB. Revising manuscript content: ZoP,
PAS, HPB. Approving final version of manuscript: EKJ, ZsP, ZoP, EK, RF, AB,
PAS, HPB. HPB takes responsibility for integrity of the data analysis.
Acknowledgements
This work is supported by the OTKA 105073 research grant (HPB) and the
TÁMOP 4.2.2.A-11/1/KONV-2012-0025 project (PAS), which is implemented
through the New Hungary Development Plan, co-financed by the European
Social Fund.
Author details
1Department of Laboratory Medicine, Faculty of Medicine, University of
Debrecen, Debrecen, Hungary. 2Department of Rheumatology, Faculty of
Medicine, University of Debrecen, Debrecen, Hungary. 3Department of
Traumatology and Hand Surgery, Faculty of Medicine, University of
Debrecen, Debrecen, Hungary. 4Regional Osteoporosis Center, Department
of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen,
Debrecen, Hungary.
Received: 4 February 2015 Accepted: 14 August 2015
References
1. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology.
2001;142:5050–5.
2. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–8.
3. Vega D, Maalouf NM, Sakhaee K. Clinical review: the role of receptor
activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin:
clinical implications. J Clin Endocrinol Metab. 2007;92:4514–21.
4. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen
stimulates gene expression and protein production of osteoprotegerin in human
osteoblastic cells. Endocrinology. 1999;140:4367–70.
5. Hofbauer LC, Hicok KC, Chen D, Khosla S. Regulation of osteoprotegerin
production by androgens and anti-androgens in human osteoblastic
lineage cells. Eur J Endocrinol. 2002;147:269–73.
6. Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear
factor-kappaB ligand and osteoprotegerin in the pathogenesis and
treatment of metabolic bone diseases. J Clin Endocrinol Metab.
2000;85:2355–63.
7. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin
serum levels in men: correlation with age, estrogen, and testosterone status.
J Clin Endocrinol Metab. 2001;86:3162–5.
8. Khosla S, Arrighi HM, Melton III LJ, Atkinson EJ, O’Fallon WM, Dunstan C,
et al. Correlates of osteoprotegerin levels in women and men. Osteoporos
Int. 2002;13:394–9.
9. Khosla S, Atkinson EJ, Dunstan CR, O’Fallon WM. Effect of estrogen versus
testosterone on circulating osteoprotegerin and other cytokine levels in
normal elderly men. J Clin Endocrinol Metab. 2002;87:1550–4.
10. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R.
Serum levels of osteoprotegerin increase with age in a healthy adult
population. Bone. 2003;32:681–6.
11. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, et al.
Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004;291:1108–13.
12. Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G. Circulating levels of
receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/
macrophage-colony stimulating factor in a presumably healthy human
population. Eur J Endocrinol. 2004;150:305–11.
13. Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, et al. Circulating
osteoprotegerin and receptor activator of NF-kappaB ligand system are
associated with bone metabolism in middle-aged males. Clin Endocrinol.
2005;62:92–8.
14. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its
relationship with bone mineral density and markers of bone turnover.
Osteoporos Int. 2005;16:417–23.
15. Mazziotti G, Amato G, Sorvillo F, Piscopo M, Rizzo MR, Lalli E, et al. Increased
serum osteoprotegerin values in long-lived subjects: different effects of
inflammation and bone metabolism. Eur J Endocrinol. 2006;154:373–7.
16. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific
association of serum osteoprotegerin and receptor activator of nuclear
factor kappaB legend with bone mineral density in older adults: the Rancho
Bernardo study. Eur J Endocrinol. 2007;156:555–62.
17. Samelson EJ, Broe KE, Demissie S, Beck TJ, Karasik D, Kathiresan S, et al. Increased
plasma osteoprotegerin concentrations are associated with indices of bone
strength of the hip. J Clin Endocrinol Metab. 2008;93:1789–95.
18. Jorgensen L, Vik A, Emaus N, Brox J, Hansen JB, Mathiesen E, et al. Bone loss
in relation to serum levels of osteoprotegerin and nuclear factor-kappaB
ligand: the Tromsø Study. Osteoporos Int. 2010;21:931–8.
19. Szulc P, Hawa G, Boutroy S, Vilayphiou N, Schoppet M, Chapurlat R,
et al. Cortical bone status is associated with serum osteoprotegerin
concentration in men: the STRAMBO study. J Clin Endocrinol Metab.
2011;96:2216–26.
20. Brage M, Lie A, Ransjö M, Kasprzykowski F, Kasprzykowska R, Abrahamson M,
et al. Osteoclastogenesis is decreased by cysteine proteinase inhibitors.
Bone. 2004;34:412–24.
21. Brage M, Abrahamson M, Lindström V, Grubb A, Lerner UH. Different
cysteine proteinases involved in bone resorption and osteoclast formation.
Calcif Tissue Int. 2005;76:439–47.
22. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the
renal function – a review. Clin Chem Lab Med. 1999;37:389–95.
23. Bhattoa HP, Nagy E, More C, Kappelmayer J, Balogh A, Kalina E, et al.
Prevalence and seasonal variation of hypovitaminosis D and its relationship
to bone metabolism in healthy Hungarian men over 50 years of age. The
HunMen Study. Osteoporos Int. 2013;24:179–86.
24. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al.
Using standardized serum creatinine values in the modification of diet in
renal disease study equation for estimating glomerular filtration rate. Ann
Intern Med. 2006;145:247–54.
25. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al.
Estimating glomerular filtration rate from serum creatinine and cystatin C.
N Engl J Med. 2012;367:20–9.
26. Teo BW, Sabanayagam C, Liao J, Toh QC, Saw S, Wong TY, et al. Comparison
of CKD-EPI cystatin C and creatinine glomerular filtration rate estimation
equations in Asian Indians. Int J Nephrol. 2014;746497.
27. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al.
Osteoprotegerin: a novel secreted protein involved in the regulation of
bone density. Cell. 1997;89:309–19.
28. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, et al. In vivo
demonstration that parathyroid hormone 1–38 inhibits the expression of
osteoprotegerin in bone with the kinetics of an immediate early gene.
J Bone Miner Res. 2000;15:863–71.
29. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits
osteoprotegerin messenger ribonucleic acid expression in murine bone
marrow cultures: correlation with osteoclast-like cell formation.
Endocrinology. 1999;140:3552–61.
30. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate
the expression of osteoclast differentiation factor and osteoprotegerin in
osteoblastic stromal cells. Endocrinology. 1998;139:4743–6.
31. Murakami T, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K,
et al. Transforming growth factor-b1 increases mRNA levels of
osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits
the survival of murine osteoclast-like cells. Biochem Biophys Res Commun.
1998;252:747–52.
32. Shaarawy M, Fathy SA, Mehany NL, Hindy OW. Circulating levels of
osteoprotegerin and receptor activator of NF-kappaB ligand in patients with
chronic renal failure. Clin Chem Lab Med. 2007;45:1498–503.
33. www.strobe-statement.org. Accessed 25 July 2015.
Kulcsar-Jakab et al. BMC Musculoskeletal Disorders  (2015) 16:227 Page 7 of 7
